Tempus AI (NASDAQ:TEM) Shares Up 1.3% – Still a Buy?

Tempus AI, Inc. (NASDAQ:TEMGet Free Report)’s share price rose 1.3% during mid-day trading on Monday . The company traded as high as $47.88 and last traded at $47.80. Approximately 3,700,512 shares were traded during trading, a decline of 25% from the average daily volume of 4,927,286 shares. The stock had previously closed at $47.17.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TEM. Loop Capital reduced their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. William Blair reiterated a “market perform” rating on shares of Tempus AI in a research report on Tuesday, February 25th. JPMorgan Chase & Co. downgraded shares of Tempus AI from an “overweight” rating to a “neutral” rating and boosted their price objective for the company from $50.00 to $55.00 in a research report on Tuesday, February 25th. TD Cowen reaffirmed a “buy” rating and issued a $74.00 target price (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Finally, Wolfe Research lowered Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Tempus AI presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.18.

Read Our Latest Report on Tempus AI

Tempus AI Stock Performance

The firm has a 50 day moving average of $55.65 and a 200-day moving average of $51.50. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insider Activity

In other Tempus AI news, major shareholder Bradley A. Keywell sold 170,720 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $35.45, for a total transaction of $6,052,024.00. Following the completion of the transaction, the insider now owns 15,993,729 shares in the company, valued at $566,977,693.05. This trade represents a 1.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Eric P. Lefkofsky sold 3,240,234 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.75, for a total value of $190,363,747.50. Following the sale, the chief executive officer now directly owns 4,895,589 shares in the company, valued at $287,615,853.75. This trade represents a 39.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,561,814 shares of company stock worth $315,485,164 over the last quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Kovitz Investment Group Partners LLC bought a new position in Tempus AI during the third quarter valued at $1,367,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Tempus AI during the 4th quarter valued at about $1,091,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Tempus AI in the 4th quarter valued at about $178,000. Captrust Financial Advisors purchased a new position in Tempus AI in the third quarter worth about $2,726,000. Finally, abrdn plc bought a new stake in Tempus AI during the fourth quarter worth approximately $2,784,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

(Get Free Report)

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Further Reading

Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.